ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-OR115

Outcomes after Left Ventricular Assist Device Implantation in Patients with AKI

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials


  • Silver, Samuel A., Queen's University, Kingston, Ontario, Canada
  • Long, Jin, Stanford University, Palo Alto, California, United States
  • Zheng, Yuanchao, Stanford University, Palo Alto, California, United States
  • Chertow, Glenn Matthew, Stanford University School of Medicine, Palo Alto, California, United States

Left ventricular assist devices (LVAD) are increasingly used as a bridge to heart transplant and destination therapy for heart failure. Although acute kidney injury (AKI) is a common complication in these patients, there are few multicenter studies on how AKI affects LVAD outcomes. We sought to determine outcomes associated with AKI among patients receiving LVADs in a nationally representative sample of hospitalizations in the US.


Using the National Inpatient Sample from 2008 to 2013, we identified patients who received a LVAD during a hospitalization using ICD-9 code 37.66. We ascertained AKI and acute dialysis using validated ICD-9 codes. The primary outcome was in-hospital mortality. Secondary outcomes included procedural complications and discharge destination. We used logistic regression to adjust for demographics, hospital-level factors, comorbidities, and acute hospitalization details.


We identified 8362 patients who received a LVAD, of whom 3760 (45%) developed AKI without dialysis (AKI-ND) and 426 (5%) developed AKI-requiring dialysis (AKI-D). In-hospital mortality increased from 4% for patients without AKI, to 12% for patients with AKI-ND, to 48% for patients with AKI-D. We observed similar increases for major bleeding (25% vs 33% vs 49%) and sepsis (9% vs 22% vs 43%). Discharge destination was home for 84% of patients without AKI, 72% of patients with AKI-ND, and 56% of patients with AKI-D. After multivariable adjustment, patients with AKI-ND and AKI-D had higher odds of mortality (OR 3.24, 95% CI 2.04-5.13 and 20.8, 95% CI 9.7-44.2), major bleeding (1.38, 95% CI 1.08-1.77 and 2.43, 95% CI 1.47-4.04), sepsis (2.69, 95% CI 1.93-3.75 and 5.75, 95% CI 3.46-9.56), and discharge to a nursing facility (2.15, 95% CI 1.51-3.07 and 5.89, 95% CI 2.67-12.99). Patients with AKI-ND and AKI-D on mechanical ventilation had a markedly increased adjusted odds of death (14.2, 95% CI 7.5-26.9 and 90.9, 95% CI 41.4-199.6). None of the patients with AKI-D received a heart transplant during the same hospitalization as LVAD implantation.


During a hospitalization in which a LVAD is implanted, patients with AKI are at increased risk of procedural complications and death. The prognosis is particularly poor for patients with AKI-D. This information is necessary to support shared decision-making for patients with advanced heart failure and AKI.